Zydus gets India nod to sell 'affordable' cancer drug amid Squibb patent dispute
An injunction against Zydus Lifesciences has been lifted by an Indian court, allowing the sale of its cheaper cancer biosimilar despite a Squibb patent dispute. The Delhi High Court cited public...To view the full article, register now.
Already a subscriber? Click here to view full article